Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

Advanced Life Sciences licenses promising technology from Argonne

DOE/Argonne National Laboratory : 21 May, 2005  (Technical Article)
Advanced Life Sciences has licensed a promising proteomics-based technology from Argonne National Laboratory. The license involves a compound called ALS-499 that has demonstrated activity in the laboratory toward inhibiting amyloid protein aggregation that is characteristic of the development of several diseases, including Alzheimer's and type-2 diabetes.
Advanced Life Sciences has licensed a promising proteomics-based technology from Argonne National Laboratory. The license involves a compound called ALS-499 that has demonstrated activity in the laboratory toward inhibiting amyloid protein aggregation that is characteristic of the development of several diseases, including Alzheimer's and type-2 diabetes.

'We believe this technology has significant potential,' said Michael T. Flavin, ALS's chief executive officer. 'It will strengthen our inflammation-fighting drug portfolio and provide us with a platform from which we can develop new drugs that may prevent a number of significant diseases. Our scientists have been working in collaboration with Argonne for several years. Our joint research led to the discovery of this interesting compound that will enhance our R&D program in inflammation therapeutics.'

Argonne, in collaboration with ALS and the University of Chicago, has been studying the biophysical foundations of amyloid formation for some time, and ALS-499 was discovered during the course of that research. The field of protein aggregation focuses on what happens when proteins in the body clump together in ways that cause disease.

'We were surprised to discover that ALS-499 blocked aggregation of a variety of proteins that can lead to several debilitating diseases,' said Fred Stevens, senior biophysicist at Argonne. 'If the compound holds substantial potential in terms of its ability to prevent diseases involving faulty protein aggregation.'

Under the terms of the license agreement, ALS, located in Woodridge, Ill., will have exclusive worldwide rights to commercialize ALS-499, as well as the platform technology, as a method for preventing amyloid fibril formation. ALS-499 will immediately advance into early stage laboratory investigation under ALS stewardship. If this compound continues to prove its effectiveness in this setting, it is likely to be slated for clinical trials within a few years.

Advanced Life Sciences is a privately held biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation using its platform in natural products and chemical proteomics coupled with expertise in drug development.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 NewMaterials.com
Netgains Logo